Daiwa Securities Group Inc. Has $1.17 Million Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Daiwa Securities Group Inc. lessened its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 11.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 111,523 shares of the company’s stock after selling 13,921 shares during the period. Daiwa Securities Group Inc.’s holdings in Teva Pharmaceutical Industries were worth $1,165,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in TEVA. Blue Trust Inc. boosted its stake in Teva Pharmaceutical Industries by 92.3% in the fourth quarter. Blue Trust Inc. now owns 4,541 shares of the company’s stock valued at $46,000 after buying an additional 2,180 shares in the last quarter. Signaturefd LLC grew its stake in shares of Teva Pharmaceutical Industries by 90.8% during the third quarter. Signaturefd LLC now owns 5,032 shares of the company’s stock worth $51,000 after buying an additional 2,394 shares during the last quarter. Desjardins Global Asset Management Inc. increased its holdings in shares of Teva Pharmaceutical Industries by 15.2% during the fourth quarter. Desjardins Global Asset Management Inc. now owns 8,123 shares of the company’s stock worth $85,000 after buying an additional 1,070 shares in the last quarter. Schechter Investment Advisors LLC bought a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at $117,000. Finally, DGS Capital Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter valued at $119,000. 54.05% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

TEVA has been the subject of a number of research reports. The Goldman Sachs Group raised their price objective on shares of Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the company a “neutral” rating in a report on Monday, February 5th. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 price objective for the company in a research report on Friday, March 8th. Piper Sandler upgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $12.00 to $19.00 in a report on Monday, February 12th. Barclays upped their price objective on shares of Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the company an “overweight” rating in a research note on Monday, February 5th. Finally, Jefferies Financial Group raised shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating and lifted their target price for the stock from $10.00 to $14.00 in a research note on Tuesday, January 23rd. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $13.78.

Teva Pharmaceutical Industries Price Performance

NYSE:TEVA opened at $13.01 on Thursday. Teva Pharmaceutical Industries Limited has a 12 month low of $7.09 and a 12 month high of $14.47. The company has a debt-to-equity ratio of 2.23, a quick ratio of 0.69 and a current ratio of 1.02. The firm has a fifty day simple moving average of $13.50 and a two-hundred day simple moving average of $11.34.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Wednesday, January 31st. The company reported $0.98 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.25. The company had revenue of $4.46 billion for the quarter, compared to analysts’ expectations of $3.97 billion. Teva Pharmaceutical Industries had a negative net margin of 3.33% and a positive return on equity of 34.90%. As a group, sell-side analysts expect that Teva Pharmaceutical Industries Limited will post 2.28 earnings per share for the current year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, VP Eric Drape sold 9,815 shares of the company’s stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $13.12, for a total transaction of $128,772.80. Following the transaction, the vice president now directly owns 9,701 shares of the company’s stock, valued at $127,277.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, VP Eric Drape sold 9,815 shares of the business’s stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $13.12, for a total transaction of $128,772.80. Following the completion of the sale, the vice president now directly owns 9,701 shares of the company’s stock, valued at $127,277.12. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Mark Sabag sold 100,000 shares of the company’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the completion of the sale, the executive vice president now owns 382,590 shares in the company, valued at approximately $5,172,616.80. The disclosure for this sale can be found here. Over the last quarter, insiders sold 390,738 shares of company stock valued at $5,132,766. Company insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.